FILING ANALYSIS · MONDAY, NOVEMBER 2
CRISPR Therapeutics AG CRSP — 8-K: Results of Operations and Financial Condition
neutral
CRISPR Therapeutics reported strong Q3 results with $99 million in CASGEVY revenue, a 30% quarter-over-quarter increase, and received FDA RMAT designations for CTX310, but no significant surprises were disclosed beyond expected progress in the pipeline.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →